Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I iPSC-derived CTL therapy for recurrent HPV16-positive cervical cancer
jRCT2033240591Phase 1Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Dec 2024
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RJB-01 in Cervical Cancer (CC), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Incidence of adverse events, Cytokine release syndrome grade and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
RJB-01
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCT2033240591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033240591.